# reload+after+2024-01-20 18:46:32.003422
address1§One Commerce Square
address2§39th Floor 2005 Market Street
city§Philadelphia
state§PA
zip§19103
country§United States
phone§267 866 0311
website§https://www.passagebio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
fullTimeEmployees§85
companyOfficers§[{'maxAge': 1, 'name': 'Dr. William  Chou M.D.', 'age': 50, 'title': 'President, CEO & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 395425, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Edgar B. Cale Esq., J.D.', 'age': 59, 'title': 'General Counsel & Company Secretary', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 674358, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James M. Wilson M.D., Ph.D.', 'age': 68, 'title': 'Co-Founder & Chief Scientific Advisor', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kathleen  Borthwick', 'age': 47, 'title': 'Senior VP of Finance, Principal Accounting Officer & Interim CFO', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stuart M. Henderson', 'title': 'Senior Vice President of Corporate Development & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Gregory  Fuest', 'title': 'Vice President of Global Commercial Strategy & Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark  Forman M.D., Ph.D.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Eden  Fucci', 'title': 'Senior Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.12
currency§USD
dateShortInterest§1702598400
forwardEps§-1.33
exchange§NMS
quoteType§EQUITY
shortName§Passage Bio, Inc.
longName§Passage Bio, Inc.
firstTradeDateEpochUtc§1582900200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f9f4ff21-d010-3b23-9d8c-0b97242aa032
gmtOffSetMilliseconds§-18000000
targetHighPrice§14.0
targetLowPrice§3.0
targetMeanPrice§7.0
targetMedianPrice§5.5
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§6.702
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
